(Fighting New Coronary Pneumonia) South African Minister of Health: The local production of the new coronary pneumonia vaccine will benefit South Africa and even Africa
China News Agency, Johannesburg, November 4 (Reporter Wang Xi) South Africa’s Health Minister Mukez expressed his appreciation at the regular press conference on the 4th for South African pharmaceutical companies’ announcement of local production of new crown pneumonia vaccines and said that this will Benefit South Africa and even Africa.
A few days ago, the South African pharmaceutical group Aspen announced that it has reached an agreement with its partners to produce the new crown pneumonia vaccine numbered "Ad26COV2-S" in Port Elizabeth in the Eastern Cape.
Mukez said that the "Ad26COV2-S" vaccine is currently undergoing Phase III clinical trials worldwide.
According to the plan, South Africa will recruit more than 10,000 volunteers from areas with severe new crown pneumonia epidemics across the country to participate in the trial.
"The current new crown pneumonia epidemic is making a comeback in individual countries in the world, making us realize that accelerating the research, development and use of new crown pneumonia vaccines has become the most urgent task."
Mukez reiterated that South Africa has been seeking opportunities for the production and use of new coronary pneumonia vaccines and has actively invested in various clinical trials.
This time, as South African companies announced that they would start local production of the new crown pneumonia vaccine, South Africa and even Africa will benefit from it. "We must ensure that no African country is left behind in the fight against the new crown pneumonia epidemic." He said.
As of press time on the 4th, the number of confirmed cases of new coronary pneumonia in South Africa reached 728,836 and 19,539 deaths.
(Finish)